Enoblituzumab
Enoblituzumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against CD276 antigen.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 2-oak mix, red/white pollen 3-oak mix, black/blackjack/post pollen 3-ragweed mix, giant/short/western pollen 4-pine mix, austrian/loblolly/scotch/w... | Biologic Licensing Application | 2011-03-11 |
| ad incontinence support | C200263 | 2025-03-07 |
| avance incontinence care | C200263 | 2026-01-12 |
| bioelements, inc. | OTC monograph not final | 2012-01-17 |
| ca-rezz - long term care - incontinent cleanser | C200263 | 2025-10-22 |
| ca-rezz - norisc - incontinent wash | C200263 | 2025-10-22 |
| center-al - acacia longifolia pollen center-al - acer negundo pollen center-al - acer saccharum pollen center-al - agrostis gigantea center-al - al... | Biologic Licensing Application | 2009-06-12 |
| chain drug marketing association, inc. | C200263 | 2025-08-22 |
| crooked creek distillery inc hand sanitizer | OTC monograph not final | 2020-03-25 |
| cvs pharmacy,inc. | C200263 | 2025-12-04 |
Show 58 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
2945 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 17 | — | — | 1 | — | 18 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
| Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | — | — | — | 1 | — | 1 |
| Urinary incontinence | D014549 | — | R32 | — | — | — | 1 | — | 1 |
| Enuresis | D004775 | — | R32 | — | — | — | 1 | — | 1 |
| Macular edema | D008269 | — | — | — | — | — | 1 | — | 1 |
| Dry eye syndromes | D015352 | — | H04.12 | — | — | — | 1 | — | 1 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rosacea | D012393 | — | L71 | — | — | 3 | — | — | 3 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | 2 | — | — | 2 |
| Actinic keratosis | D055623 | — | L57.0 | — | — | 2 | — | — | 2 |
| Keratosis | D007642 | — | — | — | — | 2 | — | — | 2 |
| Erythema | D004890 | — | L53.9 | — | — | 1 | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | — | 1 |
| Allergic rhinitis | D065631 | — | J30.9 | — | — | 1 | — | — | 1 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | — | 1 | — | — | 1 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | — | 1 | — | — | 1 |
| Ankle injuries | D016512 | — | S93.4 | — | — | 1 | — | — | 1 |
Show 14 more
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | — | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Enoblituzumab |
| INN | enoblituzumab |
| Description | Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545373 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | M6030H73N9 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Increlex – Eton Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Leqvio – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,155,854 documents
View more details
Safety
Black-box Warning
Black-box warning for: 2-oak mix, red/white pollen 3-oak mix, black/blackjack/post pollen 3-ragweed mix, giant/short/western pollen 4-pine mix, austrian/loblolly/scotch/w..., Center-al - acacia longifolia pollen center-al - acer negundo pollen center-al - acer saccharum pollen center-al - agrostis gigantea center-al - al..., Xeomin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,125 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use